IRIS
BRANCACCIO, Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.206
NA - Nord America 1.138
AS - Asia 107
SA - Sud America 13
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.131
IE - Irlanda 500
GB - Regno Unito 256
UA - Ucraina 117
IT - Italia 104
CN - Cina 79
GR - Grecia 55
SE - Svezia 55
FR - Francia 47
DE - Germania 28
FI - Finlandia 20
TR - Turchia 20
BE - Belgio 13
ET - Etiopia 5
IN - India 5
MX - Messico 5
RO - Romania 5
BO - Bolivia 4
BR - Brasile 4
EU - Europa 3
AR - Argentina 2
CA - Canada 2
PE - Perù 2
VN - Vietnam 2
AM - Armenia 1
AT - Austria 1
CH - Svizzera 1
CO - Colombia 1
CZ - Repubblica Ceca 1
HU - Ungheria 1
NL - Olanda 1
PL - Polonia 1
Totale 2.472
Salva come PNG Salva come JPEG
Città #
Dublin 500
Chandler 252
Jacksonville 198
Princeton 72
Medford 69
Roxbury 65
Houston 54
New York 50
Wilmington 27
Beijing 26
Caserta 26
Ann Arbor 22
Des Moines 22
Napoli 15
Brussels 13
Nanjing 13
Boardman 10
Bremen 10
Redwood City 9
Woodbridge 9
Ashburn 8
San Mateo 8
Mountain View 7
Nanchang 6
Rome 6
Cambridge 5
Guadalajara 5
Bagheria 4
La Paz 4
Los Angeles 4
Atlanta 3
Changsha 3
Fairfield 3
Jinan 3
Padova 3
Shanghai 3
Tianjin 3
Zhengzhou 3
Aversa 2
Catania 2
Dong Ket 2
Hebei 2
Kunming 2
Lima 2
Marano Di Napoli 2
Milan 2
Ningbo 2
Norwalk 2
Pilar 2
Shenyang 2
Taizhou 2
Vibo Valentia 2
Athens 1
Auburn Hills 1
Bogotá 1
Budapest 1
Campagna 1
Canelli 1
Castel San Giorgio 1
Chaoyang 1
Edinburgh 1
Elk Grove 1
Fuzhou 1
Gioia Del Colle 1
Groningen 1
Haikou 1
Hangzhou 1
Helsinki 1
Jiaxing 1
Lanzhou 1
London 1
Palermo 1
Parsippany 1
Portici 1
Prague 1
Richmond Hill 1
Ruvo Di Puglia 1
Stockholm 1
Tappahannock 1
Toronto 1
Trieste 1
Venice 1
Verona 1
Vienna 1
Vijayawada 1
Walnut 1
Yerevan 1
Totale 1.606
Salva come PNG Salva come JPEG
Nome #
Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays 153
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study 85
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 68
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 66
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 63
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. 61
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 59
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. 57
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 56
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 54
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 51
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. 51
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 46
Hepatitis delta infection in Italian patients: towards the end of the story? 46
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 46
Virological patterns of HCV patients with failure to interferon-free regimens. 46
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 45
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 45
AISF position paper on HCV in immunocompromised patients 45
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. 42
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 40
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 40
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. 40
Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin 39
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 37
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 37
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 37
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 37
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 36
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 36
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 36
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 36
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 36
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 34
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues. 33
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 32
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 32
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 31
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 31
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 30
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 29
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 29
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 29
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 29
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 28
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study. 28
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 27
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 27
Salvage therapy with follone by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 27
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 27
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 26
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 26
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 25
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 25
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 24
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 23
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 23
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 22
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 22
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 22
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 21
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 21
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 20
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 20
Influenza vaccination in patients with cirrosi and in liver transplant recipients. 18
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 15
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 15
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 15
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 14
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 13
Hepatitis C Virus Clearance in Older Adults 13
Platelets and hepatocellular cancer: Bridging the bench to the clinics 13
Totale 2.611
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 0 5 2
2019/2020368 57 50 10 15 33 45 57 46 14 22 17 2
2020/2021295 11 2 25 17 45 7 59 18 7 29 61 14
2021/2022510 21 9 12 21 174 8 12 24 25 26 36 142
2022/2023928 79 13 12 78 80 76 2 66 482 6 17 17
2023/2024235 29 8 12 8 115 50 0 7 0 6 0 0
Totale 2.611